Pharma Journalist -

Avantor, Inc., a global leader in life sciences and advanced technology products, has announced a strategic partnership with BlueWhale Bio, a commercial-stage company focused on…
Read More...

Johnson & Johnson has announced plans to separate its Orthopaedics division into a standalone company, DePuy Synthes, as part of a strategic move to sharpen its focus on high-growth…
Read More...

BioCryst Pharmaceuticals announced it will acquire Astria Therapeutics in a cash-and-stock deal valued at approximately $700 million, aiming to expand its portfolio of treatments for…
Read More...

Nabla Bio, a biotechnology company using generative AI to design novel therapeutics, announced a major expansion of its partnership with global pharmaceutical company Takeda. The new…
Read More...

Pfizer Inc. announced positive topline results from its Phase 3 HER2CLIMB-05 trial, marking a potential breakthrough in first-line treatment for patients with HER2-positive (HER2+)…
Read More...

Jacobio Pharma (1167.HK) announced that its subsidiary, Beijing Jacobio Pharmaceuticals Co., Ltd., has signed a Capital Increase and Equity Transfer Agreement with Oceanpine Capital and…
Read More...

Clinical-stage biotech company SystImmune has dosed the first patient in a global registrational Phase 2/3 trial for its experimental cancer therapy izalontamab brengitecan (iza-bren),…
Read More...

AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for RINVOQ (upadacitinib), broadening its use in the treatment of moderately to severely…
Read More...

The U.S. Food and Drug Administration (FDA) has approved UZEDY (risperidone) as a once-monthly, long-acting injectable for the maintenance treatment of bipolar I disorder (BD-I) in…
Read More...

Celltrion, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved EYDENZELT® (aflibercept-boav), a biosimilar to EYLEA®, for the treatment of several major…
Read More...